Bispecific Antibodies for Autoimmune and Inflammatory Diseases: Clinical Progress to Date

AbstractIn autoimmune diseases, a highly complex network comprising diverse cytokines and their receptors on immune cells drives the inflammatory response. A number of therapeutic antibodies targeting these disease-related molecules have been approved for the treatment of autoimmune diseases. Bispecific antibodies (bsAbs), with binding specificity for two different target molecules, have recently been developed for a range of autoimmune diseases, such as rheumatoid arthritis, systemic lupus erythematosus, and psoriasis, and tested in clinical trials. This review briefly describes the three main categories of bsAb structures developed for autoimmune diseases, including immunoglobulin G (IgG)-like, natural IgG, and tandem antibody fragment formats. The bsAbs developed and evaluated to date mainly target the depletion of T or B cells, the inhibition of T cell differentiation or activation, or the neutralization of proinflammatory cytokines. The clinical evaluation of bsAbs in autoimmune diseases is ongoing, with both successes (phase II trials of obexelimab in systemic lupus erythematosus) and failures (phase II trials of lutikizumab in osteoarthritis and romilkimab in idiopathic pulmonary fibrosis), and this review aims to provide a comprehensive, up-to-date summary of the clinical progress of bsAbs in this therapeutic area. Although many challenges remain, bsAbs offer new therapeutic options in the future direction of autoimmune disease treatments.
Source: BioDrugs - Category: Drugs & Pharmacology Source Type: research

Related Links:

Authors: Bardazzi F, Loi C, Vara G, Patrizi A, Di Altobrando A Abstract Objective: Rituximab, a chimeric monoclonal antibody that targets the CD-20 molecule on B-cells' surface, has led to significant advances in the treatment of autoimmune pemphigus in recent decades. The aim of the study was to assess the clinical efficacy as well as safety data for biosimilar rituximab with emphasis on the treatment of pemphigus vulgaris.Methods: A total of 12 individuals with pemphigus vulgaris treated with biosimilar rituximab were followed for at least 1 year. We assessed patient characteristics, disease history, pemphigus di...
Source: Journal of Dermatological Treatment - Category: Dermatology Tags: J Dermatolog Treat Source Type: research
Conclusions: These data suggest biomarker analysis can reflect disease activity across disease domains in PsA. Certain domains would likely benefit from evaluation of additional biomarkers. PMID: 32067517 [PubMed - as supplied by publisher]
Source: Expert Review of Clinical Immunology - Category: Allergy & Immunology Tags: Expert Rev Clin Immunol Source Type: research
Authors: Katsimardou A, Imprialos K, Stavropoulos K, Sachinidis A, Doumas M, Athyros VG Abstract Introduction: Type 1 diabetes mellitus (T1DM) is a chronic, autoimmune disease that is characterized by total absence of insulin production. Hypertension is a common comorbidity in T1DM with complex pathophysiology, while it is also a well-recognized risk factor for the development of cardiovascular disease (CVD), as well as other microvascular diabetic complications.Areas covered: The purpose of this review is to present the current definitions, epidemiological data and prevalence rates of hypertension in T1DM, as well...
Source: Expert Opinion on Pharmacotherapy - Category: Drugs & Pharmacology Tags: Expert Opin Pharmacother Source Type: research
ConclusionLET is a rare cutaneous lupus-specific lesion that may be associated with SLE. AITD, hypothyroidism in particular, could be an initial presentation of SLE. Increased awareness and early diagnosis of such clinical presentations may improve patient outcomes.
Source: The Egyptian Rheumatologist - Category: Rheumatology Source Type: research
Authors: He P, Hu Y, Huang C, Wang X, Zhang H, Zhang X, Dai H, Wang R, Gao Y Abstract Gastrodia elata is a traditional herbal medicine that has been used for centuries to treat rheumatism. Previous studies have confirmed that ethanol extracts of Gastrodia elata have anti-inflammatory and antioxidant activities, and the n-butanol fraction exerts a higher inhibitory effect. However, the in vivo anti-inflammatory effects of Gastrodia elata have not been evaluated. Thus, we assessed the therapeutic effect of the n-butanol extract of Gastrodia elata (BGE) on complete Freund's adjuvant- (CFA-) induced arthritis rats whic...
Source: Evidence-based Complementary and Alternative Medicine - Category: Complementary Medicine Tags: Evid Based Complement Alternat Med Source Type: research
Patients are optimistic about the use of artificial intelligence (AI) in radiology,...Read more on AuntMinnie.comRelated Reading: AI improves reader performance for ABUS studies AI predicts progression of osteoarthritis on x-rays AI boosts radiologists' mammography performance 14 ways AI can improve the business of radiology
Source: Headlines - Category: Radiology Source Type: news
We present the first case of simultaneous development of Graves ’ disease and type 1 diabetes during anti‐programmed cell death 1 therapy. Among Japanese participants with autoimmune polyglandular syndrome type III, the frequency of human leukocyte antigen‐DRB1*04:05 is higher in those with both type 1 diabetes and Graves’ disease. The present partic ipant carried the human leukocyte antigen‐DRB1*04:05; which might be associated with the simultaneous development of the two diseases. AbstractWe present the first case of simultaneous development of Graves ’ disease and type 1 ...
Source: Journal of Diabetes Investigation - Category: Endocrinology Authors: Tags: Case Report Source Type: research
(American Chemical Society) It seems too good to be true: a single drug that could treat humanity's worst afflictions, including atherosclerosis, cancer, Alzheimer's, Parkinson's and arthritis. All of these diseases have one thing in common -- they involve an inflammatory protein called NLRP3. Now, biotech start-ups and pharmaceutical companies are racing to develop drugs that inhibit the function of this protein, according to an article inChemical&Engineering News (C&EN), the weekly newsmagazine of the American Chemical Society.  
Source: EurekAlert! - Cancer - Category: Cancer & Oncology Source Type: news
Abstract Interleukin-29 (IL-29) is a newly discovered member of type III interferon. It mediates signal transduction via binding to its receptor complex and activates downstream signalling pathways, and therefore induces the generation of inflammatory components. Recent studies reported that expression of IL-29 is dysregulated in inflammatory autoimmune diseases, such as rheumatoid arthritis, systemic lupus erythematosus, osteoarthritis, Sjögren's syndrome, psoriasis and systemic sclerosis. Furthermore, functional analysis revealed that IL-29 may involve in the pathogenesis of the inflammatory autoimmune diso...
Source: J Cell Mol Med - Category: Molecular Biology Authors: Tags: J Cell Mol Med Source Type: research
Fight Aging! provides a weekly digest of news and commentary for thousands of subscribers interested in the latest longevity science: progress towards the medical control of aging in order to prevent age-related frailty, suffering, and disease, as well as improvements in the present understanding of what works and what doesn't work when it comes to extending healthy life. Expect to see summaries of recent advances in medical research, news from the scientific community, advocacy and fundraising initiatives to help speed work on the repair and reversal of aging, links to online resources, and much more. This content is...
Source: Fight Aging! - Category: Research Authors: Tags: Newsletters Source Type: blogs
More News: Arthritis | Autoimmune Disease | Clinical Trials | Drugs & Pharmacology | Lupus | Osteoarthritis | Psoriasis | Rheumatoid Arthritis | Rheumatology